|Articles|May 1, 2001 (Updated: November 15, 2020)
- Pharmaceutical Executive-05-01-2001
- Volume 0
- Issue 0
The Next Y2K
Author(s)Mark E. Kolb
Companies Face Costly System Overhauls With New FDA Regulations
Advertisement
Articles in this issue
almost 25 years ago
Policy: Task Mastersalmost 25 years ago
Pharmacia's Carrie Cox: HBA Woman of the Yearalmost 25 years ago
Friends of Complexityalmost 25 years ago
Under Federal Firealmost 25 years ago
Task Force: Enter the Fixersalmost 25 years ago
Political ScienceNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
2
Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion
3
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
4
Real-World Data Brings New Insights to Natural History of Disease Studies
5